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Primary cardiac lymphoma (PCL) is a rare disease entity with only a few reported cases 
in Korea. In this paper, we report a case of PCL in a 59-year-old man presenting with chest 
pain. Diffuse large B-cell lymphoma was diagnosed through a cardiac catheter-
ization-assisted percutaneous endomyocardial biopsy, and there was no evidence of ex-
tracardiac involvement of the lymphoma.The patient had a complete clinical response 
after systemic chemotherapy with a rituximab, cyclophosphamide, doxorubicin, vincris-
tine, and prednisolone (R-CHOP) regimen and additional post-chemotherapeutic radia-
tion therapy.  The patient experienced a long-term disease-free survival of over 4 years. 
However, he received coronary artery bypass graft surgery due to an acute myocardial 
infarction that occurred 3 years after the completion of the radiation therapy. Although 
the addition of radiation therapy to the treatment is thought to decrease the risk of relapse 
in patients with PCL, a careful and thorough consideration of the potential complications 
of radiation therapy, particularly with respect to cardiac complications, should be 
considered.
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INTRODUCTION
  Primary cardiac lymphoma (PCL), which makes up about 
2% of all primary cardiac tumors, is extremely rare in im-
munocompetent hosts [1]. The median age of patients with 
PCL is 64 years, and it occurs 3 times more frequently in 
women than in men [2]. PCL mainly involves the right 
atrium and the right ventricle. However, any area of the 
heart can be involved. The symptoms at initial presentation 
are nonspecific and examples of symptoms include ob-
struction of blood flow, tumor invasion to adjacent organs, 
symptoms indicating tumor emboli, treatment-refractory 
heart failure, dyspnea, arrhythmia, superior vena cava syn-
drome, and stroke. Imaging modalities such as echocardiog-
raphy (ECG), computed tomography (CT), and magnetic res-
onance imaging (MRI) are helpful, and pathologic findings 
by tissue biopsy or surgical resection are essential for a con-
firmative diagnosis. In this paper, we present a case of a 
59-year-old man who presented with chest pain. A huge 
mass in his right atrium was detected, and diffuse large 
B-cell lymphoma was diagnosed through a percutaneous en-
domyocardial biopsy. He experienced a disease-free state 
of over 4 years of outpatient follow-up, after he received 
the systemic chemotherapy regimen of rituximab, cyclo-
phosphamide, doxorubicin, vincristine, and prednisolone 
(R-CHOP) and additional post-chemotherapeutic radiation 
therapy.
CASE REPORT
  A 59-year-old man without a medical history visited a 
local clinic due to a 1-month history of chest pain. An ECG 
was performed, and a mass-like lesion was detected in the 
right atrium. He was immediately referred to the emergency 
room of our hospital. He complained of intermittent chest 
pain and dyspnea on exertion. He did not have any medical 
history or risk factors for cardiac disease. He also denied 
a family history of cardiac disease or malignancy.
  The patient’s vital signs were stable. His blood pressure 
was 121/79 mmHg, pulse rate was 76/min, respiratory rate 
was 18/min, and body temperature was 36.4
oC. His heart 
sounds exhibited a slightly accelerated regular rhythm with-
out a murmur. A fixed S2 split of his heart sounds was 
heard. His lung sounds were vesicular without crackling 
or wheezing. His bowel sounds were normoactive, and there 
was no tenderness or rebound tenderness in the abdomen. Korean J Hematol 2010;45:282-5.
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Fig. 1. (A) T2-weighted MRI image showing a cardiac mass (arrow) with similar signal intensity compared to the myocardium, and which had 
invaded the pericardial space and the right atrial wall with an intracardiac extension. (B) Biopsy specimen showing large, atypical lymphoid cells with
irregularly shaped nuclei containing clumped chromatin and prominent nucleoli (hematoxylin and eosin stain, ×400). (C) CD20 immu-
nohistochemistry of a biopsy specimen showing diffuse membranous staining. (D) A magnetic resonance image performed after 6 cycles of R-CHOP
showing a partial response of the cardiac mass (arrow). 
T h e r e  w a s  n o  o r g a n o m e g a l y  s u c h  a s  h e p a t o m e g a l y  o r  
splenomegaly. No peripheral lymphadenopathy or edema 
was detected.
  The laboratory findings of the patient’s peripheral blood 
samples were as follows: white blood cell count, 8,500/μL; 
hemoglobin, 14.4 g/dL; and platelets, 352,000/μL. The results 
of serology were as follows: HBs Ag/Ab (−/＋); anti-HCV 
(−); and anti-HIV (−). Lactate dehydrogenase (LDH) was 
elevated to 248 IU/L. A simple chest X-ray showed non-
specific findings except for mild cardiomegaly.
  An initial ECG showed a first-degree atrioventricular 
block, a right axis deviation, and a suspicious right ventricular 
hypertrophy. A transthoracic ECG showed a 6×4 cm- 
non-movable ovoid mass with a broad fundus in the atrial 
and membranous septum of the right atrium. This mass nearly 
obstructed the inflow to the right ventricle, which resulted 
in reduced diastolic volume of the right ventricle. The ejec-
tion fraction of the left ventricle was 69%, and a moderate 
amount of pericardial effusion was present.
  A chest CT showed that the poorly enhanced tumor pressed 
on both the atria and part of the left ventricle and was 
accompanied by pericardial effusion. There were no abnor-
mal findings on abdomen CT. A cardiac MRI showed a mass 
that invaded the left atrium and extended to the pericardial 
space and intra-atrial cavity (Fig. 1A). This mass encased 
the root of the aorta, the proximal part of the right coronary 
artery, and the left main coronary artery. It showed an 
iso-tense signal intensity on a T2-weighted image, a diffuse 
enhancement pattern on a contrast-weighted image, and 
an iso-tense or slightly higher signal intensity compared 
to that of cardiac muscle on a T1-weighted image. There 
were no findings suggestive of myocardial infarction. 
  A cardiac catheter-guided endomyocardial biopsy was per-
formed at 8 sites in the heart. The pathologic findings were 
consistent with diffuse large B-cell lymphoma, and the speci-
men was CD20-positive (Fig. 1B, C). The percentage area Korean J Hematol 2010;45:282-5.
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Table 1. Baseline characteristics of the long-term follow-up cases 
(≥1 year) with primary cardiac lymphoma treated with systemic 
chemotherapy (Data are from 13 cases, including the present case).
Characteristic
Cases
No. %
Total No. of cases 13
Age, years
Median 67
Range 52-77
Gender
Male 10 76.9%
Female 3 25.0%
Histologic subtype
DLBL 10 76.9%
Atypical Burkitt 1 8.3%
Other B-cell lineage 2 16.7%
Tumor localization
RA 10 76.9%
RV 1 8.3%
Atrial septum 1 8.3%
 Pericardium 1 8.3%
Abbreviations: DLBL, diffuse large B-cell lymphoma; RA, right 
atrium; RV, right ventricle.
of Ki-67 labeling was 60%. Immunoreactivity for bcl-2 and 
bcl-6 was also positive. Tumor invasion of the malignant 
lymphoma at any area except the heart was not detected 
in a bone marrow examination or in the imaging studies.
  The patient received systemic chemotherapy of a ritux-
imab, cyclophosphamide, adriamycin, vincristine, and pre-
dnisolone (R-CHOP) regimen every 3 weeks. The size of 
the mass was remarkably reduced after 1 cycle of R-CHOP, 
and further reduced after 6 cycles of chemotherapy (Fig. 
1D). The best response of R-CHOP was a partial response 
(PR).
  The patient received radiation therapy to the cardiac mass 
while in the PR state, and the total dose of radiation was 
39.6 Gy in 22 fractions. However, the size of the cardiac 
mass did not change despite the radiation therapy, and the 
disease state continued to be PR after the completion of 
the radiotherapy. The patient visited the emergency room 
due to chest pain 3 years after the completion of the radiation 
therapy. The cardiac imaging showed no change in the size 
of the cardiac tumor, whereas the findings of the coronary 
angiography showed total occlusion of the proximal part 
of the left anterior descending (LAD) coronary artery. He 
received coronary artery bypass graft surgery due to an acute 
myocardial infarction of the LAD territory.
  The disease state of the patient has been complete clinical 
remission over the 4 years since the initial diagnosis of PCL.
DISCUSSION
  To our knowledge, this is the first report of a case with 
long-term disease-free survival in a Korean patient with 
PCL treated with systemic chemotherapy combined with 
post-chemotherapeutic radiation therapy. A summary of cas-
es of PCL in Korea is available elsewhere [3].
  In order to compare this case with previous reports of 
patients with PCL, we searched case reports from the database 
of the National Library of Medicine of the United States 
(http://www.ncbi.nlm.nih.gov/pubmed/) according to the 
following criteria: (1) published from Jan 1995 to Dec 2009, 
(2) treated with systemic chemotherapy (except adjuvant 
chemotherapy), (3) long-term follow-up data (≥1 years) 
was available, and (4) written in English. We found 12 cases 
that met our criteria. The analysis of the previous reports 
showed that the predominant gender was male (75.0%).  
The most common histologic subtype was diffuse large B-cell 
lymphoma, and the most frequent site of the tumor was 
the right atrium (Table 1). The most frequent location of 
PCL reported in our results was different from that of myx-
oma, which is the most common primary cardiac tumor.
  The clinical presentation of PCL is nonspecific, and hence, 
an imaging study that is conducted because of a suspicion 
for PCL is essential to the initial diagnosis. There are a 
few primary cardiac malignancies that mimic PCL, such as 
angiosarcoma and rhabdomyosarcoma. Angiosarcoma is also 
often located within the right atrium.
  Angiosarcoma is usually located in the central region and 
shows an iso-tense signal intensity, which is consistent with 
central necrosis on T1-weighted images, whereas PCL shows 
a nodular mass without intratumoral necrosis of an iso-tense 
signal intensity on T1-weighted images. Rhabdomyosarcoma 
that originates from the myocardium has no favorable loca-
tion and frequently invades the valvular structure.  An imag-
ing study of rhabdomyosarcoma shows a huge mass with 
central necrosis and a characteristic inhomogeneous signal 
intensity on T1- and T2-weighted images [4]. Despite the 
few differential considerations of primary cardiac malig-
nancies described above, imaging modalities cannot be con-
firmative to diagnosis. For example, PCL may have less en-
hanced central regions, which is consistent with necrosis 
[5]. Thus, a final confirmative diagnosis should be proven 
through pathology.
  Although fluorine-18 fluorodeoxyglucose (
18F-FDG) posi-
tron emission tomography (PET)-CT is performed for the 
staging in many cases, the diagnostic sensitivity of a cardiac 
lesion is very low because the baseline 
18FDG uptake of 
the heart is very high [6]. Therefore, CT and MRI, rather 
than PET-CT, were performed in the evaluation of our 
patient.
  The standard treatment option of PCL is not well estab-
lished, and various treatment modalities, such as surgical 
resection, systemic chemotherapy, radiation therapy, and 
combined treatments, have been attempted. The analysis 
of the 13 case reports, including the current case report, 
showed that all patients received anthracycline-containing 
combination chemotherapy with or without additional 
post-chemotherapeutic radiation therapy. Although the 
number of patients enrolled in our analysis was too small Korean J Hematol 2010;45:282-5.
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Table 2. Long-term outcomes of cases of primary cardiac lymphoma
treated with systemic chemotherapy (Data are from 13 cases, 
including the one detailed in the current case report).
Treatment
Cases  Long-term outcomes
N %
Median PFS, 
months (range)
Relapsed
cases (N)
Chemotherapy
 regimen
a)
Non-rituximab-
 containing
9 69.2% 12.0
(6.0-60.0)
2
Rituximab-
 containing
4 30.8% 24.0
(11.0-48.0)
1
Additional post-
 chemotherapy RTx
Not done 9 69.2% 12.0
(6.0-48.0)
3
Done 4 30.8% 41.0
(12.0-60.0)
0
a)All patients received anthracycline-containing combination che-
motherapy.
Abbreviations: PFS, progression free survival; RTx, radiation therapy.
to elicit statistical significance, our analysis of the case reports 
of PCL showed that the patients who were treated with 
a combined modality of systemic chemotherapy and addi-
tional post-chemotherapeutic radiation therapy had a better 
long-term progression-free survival (PFS) compared to those 
treated with systemic chemotherapy alone (median PFS, 41.0 
months vs. 12.0 months). Furthermore, no recurrence of 
lymphoma was noted in the patients who received both 
systemic chemotherapy and additional post-chemothera-
peutic radiation therapy. 
  The patients who received rituximab-containing regimens 
had a longer PFS compared to those who received non-ritux-
imab-containing regimens (median PFS, 24.0 months vs. 12.0 
months). However, 1 case of recurrence was noted among 
the patients who had received rituximab-containing regi-
mens (Table 2). 
  Our analysis of this small case series of PCL patients showed 
that the combined treatment of chemotherapy and post-che-
motherapeutic radiation therapy decreased the risk of 
relapse. The cardiac mass of the patient in our case showed 
a residual lesion that was unchanged for a long time after 
the completion of the radiation therapy, which suggested 
the probability that non-tumorous fibrous tissue replaced 
the original tumor subsequent to the chemotherapy-induced 
tumor necrosis.
  Although cases of cardiac perforation as an initial pre-
sentation have been reported [7, 8], a post-chemotherapeutic 
complication of a cardiac perforation has not been reported 
yet. However, radiation therapy to the heart has been known 
to cause cardiac complications. A previous report showed 
that myocardial infarction developed in 4.5% of non-small 
cell lung cancer patients who had received previous radiation 
therapy [9], and another report of 415 patients with Ho-
dgkin’s disease [10] showed that coronary artery disease de-
veloped in 42 patients (10.4%), a median of 9 years after 
radiation therapy. Other cardiac diseases such as valvular 
heart disease, pericardial disease, and cardiomyopathy have 
also been reported.
  Although the patient described in this case report had 
no risk factors for coronary artery disease, an acute my-
ocardial infarction developed 3 years after the completion 
of radiation therapy, and was successfully treated by coronary 
artery bypass graft surgery. Although the addition of radia-
tion therapy is thought to decrease the risk of relapse in 
the treatment of patients with PCL, a careful and thorough 
consideration of the potential complications of radiation 
therapy should be considered.
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